argenx announces Annual General Meeting of Shareholders on May 11, 2021
30 Marzo 2021 - 10:00PM
March 30, 2021
Breda, the Netherlands – argenx
SE (Euronext & Nasdaq: ARGX), a global immunology company
committed to improving the lives of people suffering from severe
autoimmune diseases and cancer, today announced that an annual
general meeting of shareholders will be held at 10:00 a.m. CEST on
Tuesday May 11, 2021 at the Hilton Amsterdam Airport Schiphol,
Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands. The
shareholders and all other persons with meeting rights are invited
to attend the annual general meeting of shareholders.
The formal notice of convocation (including
information on attending the meeting in person or by proxy,
requirements for notification and registration for the meeting and
regarding the e-voting system) is available on the argenx website
www.argenx.com and on www.abnamro.com/evoting.
Agenda The full agenda for the
meeting as well as all ancillary documents relevant for the meeting
are available via the argenx website and are also available for
inspection at the argenx offices. A free copy thereof may also be
obtained by e-mailing annualmeeting@argenx.com.
In addition to recurrent items on the agenda,
such as the discussion and adoption of the 2020 Annual Accounts, an
advisory vote on the company’s remuneration report, the discharge
of the directors for their duties performed in 2020 and the
authorization of the Board of Directors to issue shares and to
limit or exclude pre-emptive rights in relation thereto, the
following items, amongst others, are proposed:
- Approval of the updated and amended remuneration policy;
- Appointment of Yvonne Greenstreet and re-appointment of Anthony
Rosenberg as non-executive directors to the Board of Directors;
and
- Appointment of Deloitte Accountants B.V. for the 2021 financial
year.
Due to the ongoing COVID-19 pandemic, argenx
would like to encourage shareholders to use the voting by
(electronic) proxy option as referred to in the convocation. The
Company will provide a live audio-webcast of the general meeting to
enable as many shareholders as possible to attend.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer.
Partnering with leading academic researchers through its Immunology
Innovation Program (IIP), argenx aims to translate immunology
breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx is evaluating efgartigimod in multiple serious
autoimmune diseases, and cusatuzumab in hematological cancers in
collaboration with Janssen. argenx is also advancing several
earlier stage experimental medicines within its therapeutic
franchises. argenx has offices in Belgium, the United States, Japan
and Switzerland. For more information,
visit www.argenx.com and follow us on LinkedIn at
https://www.linkedin.com/company/argenx/ and Twitter at
https://twitter.com/argenxglobal.
For further information, please
contact:
Investors: Beth
DelGiacco (US)bdelgiacco@argenx.com
Joke Comijn (EU) jcomijn@argenx.com
Forward-looking Statements
The contents of this announcement include
statements that are, or may be deemed to be, “forward-looking
statements.” These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“believes,” “estimates,” “anticipates,” “expects,” “intends,”
“may,” “will,” or “should” and include statements argenx makes
concerning its 2021 business and financial outlook and related
plans; the therapeutic potential of its product candidates;
the intended results of its strategy and argenx’s, and its
collaboration partners’, advancement of, and anticipated clinical
development, data readouts and regulatory milestones and plans,
including the timing of planned clinical trials and expected data
readouts; the design of future clinical trials and the
timing and outcome of regulatory filings and regulatory
approvals. By their nature, forward-looking statements involve
risks and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. argenx’s actual results may differ
materially from those predicted by the forward-looking statements
as a result of various important factors, including the
effects of the COVID-19 pandemic, argenx’s expectations
regarding its the inherent uncertainties associated with
competitive developments, preclinical and clinical trial and
product development activities and regulatory approval
requirements; argenx’s reliance on collaborations with
third parties; estimating the commercial potential
of argenx’s product
candidates; argenx’s ability to obtain and maintain
protection of intellectual property for its technologies and
drugs; argenx’s limited operating history;
and argenx’s ability to obtain additional funding for
operations and to complete the development and commercialization of
its product candidates. A further list and description of these
risks, uncertainties and other risks can be found
in argenx’s U.S. Securities and Exchange Commission (SEC)
filings and reports, including in argenx’s most recent
annual report on Form 20-F filed with the SEC as well as subsequent
filings and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. argenx undertakes no obligation to publicly update or
revise the information in this press release, including any
forward-looking statements, except as may be required by
law.
- PR210331 argenx announces 2021 AGM FINAL
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Apr 2023 a Apr 2024